Lutetium LU-177 Vipivotide Tetraxetan
Protein
Overview
Lutetium LU-177 Vipivotide Tetraxetan is a protein active pharmaceutical ingredient (ChEMBL CHEMBL4594406).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Lutetium LU-177 Vipivotide Tetraxetan expires 18 Sept 2041 and exclusivity 31 Jul 2029. Generic API sourcing typically opens up once these lapse.
Verified Supplier Partner
Do you supply Lutetium LU-177 Vipivotide Tetraxetan? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.